Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (CONTINUUM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03700476 |
Recruitment Status :
Active, not recruiting
First Posted : October 9, 2018
Last Update Posted : March 28, 2023
|
Sponsor:
Sun Yat-sen University
Collaborator:
Innovent Biologics (Suzhou) Co. Ltd.
Information provided by (Responsible Party):
Jun Ma, MD, Sun Yat-sen University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Actual Primary Completion Date : | February 28, 2023 |
Estimated Study Completion Date : | January 2025 |